| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 09/10/2003 | CN1441785A Tetrahydroixoquinoline analogs useful as growth hormone secretagogues |
| 09/10/2003 | CN1441782A N-oxides as NK1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives |
| 09/10/2003 | CN1441781A Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity |
| 09/10/2003 | CN1441774A Novel dicarboxylic acid derivatives |
| 09/10/2003 | CN1441773A Cyclohexylamine derivative as subtype selective NMDA receptor Antagonists |
| 09/10/2003 | CN1441770A Modified forms of pharmacologically active agents and uses therefor |
| 09/10/2003 | CN1441679A Compositions containing therapentically active components having enhanced solubility |
| 09/10/2003 | CN1441675A Compositions and methods for achieving immune suppression |
| 09/10/2003 | CN1441673A 4,5-dihydro-thiazo-2-ylamine derivatives and their use as NO-synthase inhibitors |
| 09/10/2003 | CN1441667A Pharmaceutical compositions |
| 09/10/2003 | CN1441666A Macromolecular drug complexes and compositions containing same |
| 09/10/2003 | CN1440979A Steroid saponin from sealwort as Chinese medicine material and its medicinal use and prepn process |
| 09/10/2003 | CN1440971A Vitronectin receptor antagnist, its preparation and use |
| 09/10/2003 | CN1440803A Migraine treating Chinese medicine |
| 09/10/2003 | CN1440745A Fluoxetine medicinal preparation |
| 09/10/2003 | CN1440744A Coated nano melatonin composite health tonic |
| 09/10/2003 | CN1120842C New thiazole benzimidazole derivative |
| 09/10/2003 | CN1120706C Use of ursonic acid in preparation of depression treatment medicine |
| 09/09/2003 | US6617452 Liquid-liquid extraction being carried out in the first stage at a pH-value of about 4; treating narrow-angle glaucoma, Alzheimer's disease, as well as alcohol and nicotine dependence. |
| 09/09/2003 | US6617440 Isolated polynucleotide that promotes transcription; gene expression inhibition; used for engineering animals with increased lean meat and promoting muscle growth; treating muscular disorders |
| 09/09/2003 | US6617431 Recombinant collagen and derived proteins produced by plants, methods for obtaining them and uses |
| 09/09/2003 | US6617430 Ataxin-2 binding proteins |
| 09/09/2003 | US6617426 Peptide analogs of given formula; useful in treating neurodegenerative, autoimmune, cognitive disorders, stroke and traumatic injury |
| 09/09/2003 | US6617361 Protocol for prevention of Alzheimer's disease involves stimulating implicit memory; psychotherapeutic or psychological supports; stimulating explicit memory; transfers learned behavior into the implicit memory. |
| 09/09/2003 | US6617359 4-fluoro-N-indan-2-yl benzamide and its use as a pharmaceutical |
| 09/09/2003 | US6617358 Also bis(optionally chloro- or fluoro-substitutedphenyl)alkylcarboxy acids and esters |
| 09/09/2003 | US6617353 Prostaglandin derivtives substituted with hydroxypropynyl and carboxyalkylthioalkyl groups, dispersed in a water-soluble polymer; used to treat sleep disorders |
| 09/09/2003 | US6617344 Heterocyclically substituted benzoylguanidines, process for their preparation, their use as medicaments or diagnostics, and medicaments comprising them |
| 09/09/2003 | US6617336 Treatment of urinary incontinence, venous insufficiency, migraine or gastrointestinal disorders |
| 09/09/2003 | US6617331 Purine inhibitors of protein kinases, G proteins and polymerases |
| 09/09/2003 | US6617327 For therapy of depression and other diseases such as obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders |
| 09/09/2003 | US6617326 Imidazo-triazine derivatives as ligands for GABA receptors |
| 09/09/2003 | US6617322 Administering a piperazine or piperidine coupled through a linker to a benzhydril |
| 09/09/2003 | US6617311 Effecting an increase in the amount of TH within the CNS through increasing the effective amount of an analog of Gly-Pro-Glu tripeptide (GPE) within the CNS of said patient; analog may be GP or PE. t |
| 09/09/2003 | US6617122 Contacting a compound with a polypeptide, in the presence of adenosine triphosphate (ATP) and detecting its binding or hydrolysis of ATP; use in treatment of coronary artery disease |
| 09/09/2003 | US6616943 Composition comprising Wenguanguo extracts and methods for preparing same |
| 09/09/2003 | CA2360287C Crystalline base of citalopram |
| 09/09/2003 | CA2263566C Substituted 6,5-hetero-bicyclic derivatives |
| 09/09/2003 | CA2138026C Novel 1,4-dihydroquinoxaline-2,3-diones and uses therefor as glycine receptor antagonists |
| 09/09/2003 | CA2078814C Substituted pyridinylamino-1h-indoles, 1h-indazoles, 2h-indazoles, benzo[b]thiophenes and 1,2-benzisothiazoles, a process for their preparation and their use as medicaments |
| 09/09/2003 | CA2036770C Inhibitors of nitric oxide biosynthesis |
| 09/04/2003 | WO2003073107A2 Neuropeptide receptor and uses thereof |
| 09/04/2003 | WO2003073062A2 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors |
| 09/04/2003 | WO2003072801A2 Compositions and method for regulation of calcium-dependent signalling in brain |
| 09/04/2003 | WO2003072780A1 Novel proteins, dnas thereof and use of the same |
| 09/04/2003 | WO2003072734A2 Bipolar trans carotenoid salts and their uses |
| 09/04/2003 | WO2003072704A2 RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET DERIVED GROWTH FACTOR (PDGF) AND PLATELET DERIVED GROWTH FACTOR RECEPTOR (PDGFR) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 09/04/2003 | WO2003072580A1 1-[ALKYL], 1-[HETEROARYL)ALKYL] AND 1-[ARYL)ALKYL]-7-(PYRIMIDIN-4-YL)-IMADAZO[1,2-a]PYRIMIDIN-5(1H)-ONE DERIVATIVES |
| 09/04/2003 | WO2003072579A1 HETEROARYL SUBSTITUTED 2-PYRIDINYL AND 2-PYRIMIDINYL -6,7,8,9- TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES |
| 09/04/2003 | WO2003072578A1 Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity |
| 09/04/2003 | WO2003072572A1 Beta3-adrenergic receptor agonists |
| 09/04/2003 | WO2003072569A1 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases |
| 09/04/2003 | WO2003072565A1 Process for the production of citalopram |
| 09/04/2003 | WO2003072564A1 Purification of citalopram |
| 09/04/2003 | WO2003072563A1 Amorphous citalopram salts |
| 09/04/2003 | WO2003072562A1 Amorphous citalopram |
| 09/04/2003 | WO2003072558A2 Arylsulfone derivatives |
| 09/04/2003 | WO2003072556A1 Glutaminyl based dpiv inhibitors |
| 09/04/2003 | WO2003072554A1 Azole compounds |
| 09/04/2003 | WO2003072552A1 Method for preparing benzisoxazole methane sulfonyl chloride and its amidation to form zonisamide |
| 09/04/2003 | WO2003072550A1 Novel fused ring indazole compounds |
| 09/04/2003 | WO2003072548A1 Pyridyl sulfone derivatives as 5-ht receptor antagonists |
| 09/04/2003 | WO2003072544A1 Crystalline anhydrous and monohydrate benzoate salts of (2's,3s)-3-hydroxy-n-{2{n-methyl-n-4-(n-propylamino-carbonyl)phenyl]amino-2-phenyl}-ethylpyrrolidine |
| 09/04/2003 | WO2003072543A2 Methods of preventing or treating brain ischemia or brain injury |
| 09/04/2003 | WO2003072539A1 Phenethanolamine derivatives for treatment of respiratory diseases |
| 09/04/2003 | WO2003072535A2 Substituted hydroxyethylamines |
| 09/04/2003 | WO2003072528A2 (substituted)acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases |
| 09/04/2003 | WO2003072138A1 Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents |
| 09/04/2003 | WO2003072135A2 Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors |
| 09/04/2003 | WO2003072111A2 Omega-3 fatty acids or omega-3 phosphatidylcholine in the treatment of depression |
| 09/04/2003 | WO2003072110A1 Use of biogenic estriol diester prodrugs for the treatment of autoimmune diseases |
| 09/04/2003 | WO2003072109A1 Use of biogenic estriol sulfamate prodrugs for the treatment of autoimmune diseases |
| 09/04/2003 | WO2003072107A1 Substituted pyrimidinones and pyrimidinthiones |
| 09/04/2003 | WO2003072106A2 Use of tyrosine kinase inhibitors for treating substance use disorders |
| 09/04/2003 | WO2003072104A1 Preparation of paroxetine involving novel intermediates |
| 09/04/2003 | WO2003072101A1 2-methylthiazolidine-2,4-dicarboxylic acid and the salts thereof used for the treatment of neurodegenerative diseases |
| 09/04/2003 | WO2003072094A1 Ambroxol for treating painful conditions in the mouth and pharyngeal cavity |
| 09/04/2003 | WO2003072090A2 Use of tyrosine kinase inhibitors for treating cns disorders |
| 09/04/2003 | WO2003072062A2 Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders |
| 09/04/2003 | WO2003072055A2 Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective mao inhibitors |
| 09/04/2003 | WO2003072046A2 Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances |
| 09/04/2003 | WO2003072040A2 Administration of agents for the treatment of inflammation |
| 09/04/2003 | WO2003072035A2 Compositions and methods for the treatment of immune related diseases |
| 09/04/2003 | WO2003072027A2 Compositions and formulations of 9- nitrocamptothecin polymorphs and methods of use thereof |
| 09/04/2003 | WO2003071922A2 Use of modulators of nicotinic receptors for treatment of cognitive dysfunction |
| 09/04/2003 | WO2003064472A3 Treatment of ms with goat serum |
| 09/04/2003 | WO2003062209A3 Substituted quinazolin-4-ylamine analogues as modulators of capsaicin |
| 09/04/2003 | WO2003053224A3 Novel compositions and methods for cancer |
| 09/04/2003 | WO2003051805A3 Substituted phenyl naphthalenes as estrogenic agents |
| 09/04/2003 | WO2003051302A3 Methods and compositions for treatment of central nervous system disorders |
| 09/04/2003 | WO2003048120A3 2-aryl pyrrologpyrimidines for a1 and a3 receptors |
| 09/04/2003 | WO2003045991A3 Complement c3 precursor biopolymer markers predictive of alzheimers disease |
| 09/04/2003 | WO2003045313A3 2-aminoquinoline compounds |
| 09/04/2003 | WO2003037891A8 Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors) |
| 09/04/2003 | WO2003035646A3 Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-ht2b receptor antagonist |
| 09/04/2003 | WO2003029423A3 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 09/04/2003 | WO2003020273A3 Pharmaceutical composition comprising gabapentin or an analogue thereof and an $g(a)-aminoamide and its analgesic use |
| 09/04/2003 | WO2003015760A8 Use of dmso in the treatment of neurodegenerative diseases caused by prions |
| 09/04/2003 | WO2003011860A3 2-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-N-[6-(1,1-DIOXO-1λ6-THIOMORPHOLIN-4-YL)-4-(2-METHYL OR 4-FLUORO-2-METHYL SUBSTITUTED)PHENYL-PYRIDIN-3-YL]-N-METHYL-ISOBUTYRAMIDE |
| 09/04/2003 | WO2003005967A3 Dual release levodopa ethyl ester and decarboxylase in controlled release core |